Skip Ribbon Commands
Skip to main content

Clin Asst Prof Chan Junjie Jack

Clin Asst Prof Chan Junjie Jack

MBBS, MRCP (UK), M Med (Internal Medicine), FAMS

Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Breast, Gynae-Oncology

Conditions Treated by this Doctor:
Breast Cancer , Gynaecological Cancers.

Clinical Appointments

  • Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Assistant Prof at Duke-NUS Medical School

Profile

Dr Jack Chan is a Consultant in the Division of Medical Oncology at National Cancer Centre Singapore, and a Visiting Consultant with Department of Gynaecological Oncology at KK Women’s and Children’s Hospital. Dr Chan completed his specialist training in Medical Oncology at NCCS, and is a Fellow of the Academy of Medicine, Singapore. He did his advanced fellowship in early drug development and translational medicine in gynaecological cancers at Cancer Research UK Edinburgh Centre and Edinburgh Cancer Centre under the Health Manpower Development Plan Award.

Dr Chan’s subspecialty interests are gynaecological cancers and breast cancer. His research interests include early and late phase clinical trials and translational work in gynaecological and breast cancers. He is the Principal Investigator of investigator-initiated and industry-sponsored trials at NCCS. Dr Chan is also active in teaching Senior Residents, medical officers, medical and nursing students; as well as in professional societies such as the Gynecological Cancer Group Singapore and College of Physicians, Academy of Medicine, Singapore. He has received accolades for his education and clinical work, including Residency in SingHealth Excels Outstanding Faculty Award 2020 and Singapore Health Quality Service Awards (Silver 2019, Gold 2020).

Dr Chan believes in taking a personalised approach to cancer care. He strives to support his patients and their families through navigating the cancer journey by addressing both their medical needs and quality of life.

Education

  • Fellow of Academy of Medicine Singapore, Chapter of Medical Oncologists, College of Physicians, 2018
  • Member of Royal College of Physicians (UK); Master of Medicine (Internal Medicine) (Singapore), 2012
  • Bachelor of Medicine and Bachelor of Surgery, 2008

Professional Appointments and Committee Memberships

  • Clinical Core Faculty Member, SingHealth Medical Oncology Residency Programme
  • Clinical Lecturer, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore

Awards

  • Residency in SingHealth Excels Outstanding Faculty Award, 2020
  • Singapore Health Quality Service Gold Award, 2020
  • Singapore Health Quality Service Silver Award, 2019
  • Residency in SingHealth Excels Outstanding Resident Award, 2015
  • SingHealth Best House Officer Award, 2009
  • Meritorious House Officer Award, Yong Loo Lin School of Medicine, National University of Singapore, 2009
  • Dean’s List, Yong Loo Lin School of Medicine, National University of Singapore, 2004, 2005, 2007

Research Interests

Publications

  • Ng DQ, Tan CJ, Soh BC, Tan MML, Loh S, Tan YE, Ong HH, Teng PPC, Chan JJ, Chay WY, Lee J, Lai GGY, Beh SY, Tan T, Yap YS, Lee GE, Wong M, Dent R, Lo Y, Chan A, Loh KW. Impact of cryotherapy on sensory, motor, and autonomic neuropathy in breast cancer patients receiving paclitaxel: a randomized, controlled trial. Front Neurol 2020; 11:604688.

  • Chan JJ, Tan TJY, Dent RA. Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer. Curr Opin Oncol 2020; 32(6):575-84.

  • Chan JJ, Sim Y, Ow SGW, Lim JSJ, Kusumawidjaja G, Zhuang Q, Wong RX, Wong FY, Tan VKM, Tan TJY. The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience. Endocr Relat Cancer 2020; 27(9):R307-27.

  • Chan JJ, Tan TJY, Dent RA. Novel therapeutic avenues in triple negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Ther Adv Med Oncol 2019; 11:1758835919880429.

  • Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KW, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, Chan A. Replication and meta-analysis of the association between BDNF Val66Met polymorphism and cognitive impairment in patients receiving chemotherapy. Mol Neurobiol 2019; 56(7):4741-50.

  • Chan JJ, Tan TJY, Dent RA. Are there any clinically relevant subgroups of triple-negative breast cancer in 2018? J Oncol Pract 2018; 14(5): 281-9.

  • Tan TJ, Chan JJ, Kamis S, Dent R. What is the role of immunotherapy in breast cancer. Chin Clin Oncol 2018; 7(2): 13.

  • Lee JXJ, Chan JJ, Choo SP. Clinical development of c-MET inhibition in hepatocellular carcinoma. Diseases 2015; 3(4): 306-24.

Research Trials

  • Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02) (ClinicalTrials.gov Identifier: NCT04620954) (Principal Investigator)

  • Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-01) (ClinicalTrials.gov Identifier: NCT03100006) (Principal Investigator)